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OBJECTIVE—Glucagon-like peptide-1 (7-36)amide (GLP-1) is
cleaved by dipeptidyl peptidase-4 (DPP-4) to GLP-1 (9-36)amide.
We examined whether chemical inhibition or genetic elimination
of DPP-4 activity affects cardiovascular function in normoglyce-
mic and diabetic mice after experimental myocardial infarction.
RESEARCH DESIGN AND METHODS—Cardiac structure
and function was assessed by hemodynamic monitoring and
echocardiography in DPP-4 knockout (Dpp4
/) mice versus
wild-type (Dpp4
/) littermate controls and after left anterior
descending (LAD) coronary artery ligation–induced myocardial
infarction (MI). Effects of sustained DPP-4 inhibition with sita-
gliptin versus treatment with metformin were ascertained after
experimental MI in a high-fat diet–streptozotocin model of mu-
rine diabetes. Functional recovery from ischemia-reperfusion
(I/R) injury was measured in isolated hearts from Dpp4
/
versus Dpp4
/ littermates and from normoglycemic wild-type
(WT) mice treated with sitagliptin or metformin. Cardioprotec-
tive signaling in the murine heart was examined by RT-PCR and
Western blot analyses.
RESULTS—Dpp4
/ mice exhibited normal indexes of cardiac
structure and function. Survival post-MI was modestly improved
in normoglycemic Dpp4
/ mice. Increased cardiac expression
of phosphorylated AKT (pAKT), pGSK3, and atrial natriuretic
peptide (ANP) was detected in the nonischemic Dpp4
/ heart,
and HO-1, ANP, and pGSK3 proteins were induced in nonisch-
emic hearts from diabetic mice treated with sitagliptin or met-
formin. Sitagliptin and metformin treatment of wild-type diabetic
mice reduced mortality after myocardial infarction. Sitagliptin
improved functional recovery after I/R injury ex vivo in WT mice
with similar protection from I/R injury also manifest in hearts
from Dpp4
/ versus Dpp4
/ mice.
CONCLUSIONS—Genetic disruption or chemical inhibition of
DPP-4 does not impair cardiovascular function in the normogly-
cemic or diabetic mouse heart. Diabetes 59:1063–1073, 2010
T
ype 2 diabetes is associated with an increased
risk of cardiovascular disease, hence there is
considerable interest in strategies that reduce
cardiovascular morbidity and mortality in dia-
betic subjects. Although aggressive treatment of blood
pressure and dyslipidemia reduces cardiovascular events
in both nondiabetic and diabetic patients, whether reduc-
tion in blood glucose alone reduces cardiac events in
subjects with established diabetes remains controversial
(1). Moreover, pharmacotherapy of diabetes using agents
with unique antidiabetic mechanisms may be associated
with differential and occasionally unexpected adverse
effects on cardiovascular outcomes, independent of effects
on glucose control (2,3). Therefore, a detailed understand-
ing of the unique cardiovascular beneﬁts and risks of each
antidiabetic drug used to treat diabetes seems prudent.
The two most recently approved drug categories for the
treatment of type 2 diabetes, GLP-1 receptor (GLP-1R)
agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors,
exert their antidiabetic actions largely through potentia-
tion of GLP-1R activation (4). Because these agents have
only been used clinically for several years, there are scant
data on cardiovascular outcomes associated with these
incretin-based therapies. GLP-1 improves endothelial func-
tion in subjects with type 2 diabetes (5), and transient
GLP-1 administration improves cardiovascular outcomes
in subjects with myocardial infarction (MI) or congestive
heart failure (CHF) (6,7). Moreover, preclinical data dem-
onstrate that GLP-1 is cardioprotective when administered
before the induction of ischemia (8–10). Furthermore,
therapy with the GLP-1R agonists exenatide and liraglutide
is associated with blood pressure reduction in the majority
of treated subjects (11,12). Hence, although limited, the
available data support the hypothesis that antidiabetic
therapy with GLP-1 may be associated with beneﬁcial
effects on cardiovascular outcomes. Nevertheless, as
GLP-1R agonists may produce weight loss (13), the extent
to which the salutary effects of GLP-1R activation on the
cardiovascular system in vivo reﬂect the beneﬁcial conse-
quences of weight loss remains unclear.
In contrast, much less is known about the cardiovascu-
lar biology of DPP-4. Unlike therapy with GLP-1R agonists,
the use of sitagliptin, saxagliptin, or vildagliptin has not
been associated with weight loss or sustained improve-
ment in lipid proﬁles (4). Moreover, inhibition of DPP-4
enzyme activity modulates the activity of cardioactive
peptides such as brain natriuretic peptide, neuropeptide Y,
and stromal cell–derived factor-1 (SDF-1) (14) via non–
GLP-1 mechanisms of action. More recently, GLP-1 (9-36),
a peptide metabolite derived from native GLP-1 (7-
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exert cardioprotective actions in rodents (15,16) and im-
prove cardiovascular function in dogs with CHF (17).
Accordingly, to delineate the importance of DPP-4 for
cardiovascular biology in vivo, we studied cardiovascular
function in Dpp4
/ mice in vivo, in isolated perfused
Dpp4
/ and Dpp4
/ hearts ex vivo, and in wild-type
diabetic mice subjected to experimental MI and treated
with the DPP-4 inhibitor sitagliptin.
RESEARCH DESIGN AND METHODS
Animal models and drug treatments. Experimental procedures adhered to
approved protocols of the University Health Network and Mt. Sinai Hospital
Animal Care Committees. Mice were housed under pathogen-free conditions
in micro-isolator cages and maintained on a 12-h light (0700)/dark (1900) cycle
with access to standard rodent food and water ad libitum, except where
noted. All experiments used age- and sex-matched littermates. Dpp4
/ mice
were inbred on the C57BL/6 background (18). Experimental animals were
derived by crosses between heterozygous Dpp4
/ mice to generate Dpp4
/
and Dpp4
/ littermate mice. All genotypes were conﬁrmed by PCR analyses
of tail DNA.
C57BL/6 mice, 4 weeks old, were purchased from Taconic (Germantown,
NY) and housed as described above, but placed on a high-fat diet (HFD: 45%
kcal from fat; Research Diets, New Brunswick, NJ). After 5 weeks of HFD,
mice were fasted for 5 h and then injected with a single dose of streptozotocin
(STZ; Sigma) (75 mg/kg i.p.) as a freshly prepared solution in 0.1 mmol/l
sodium citrate, pH 5.5. Mice were then randomized to treatment with either
HFD alone, HFD plus a DPP-4 inhibitor (sitagliptin, 250 mg  kg
1  day
1) (19),
or HFD plus metformin (450 mg  kg
1  day
1). The dose of metformin was
chosen based on related studies (20) and following pilot studies demonstrat-
ing optimal antidiabetic actions without signiﬁcant effects on food intake or
body weight. This dose of sitagliptin does not affect food intake, yet results in
90% inhibition of DPP-4 (19,21). Sitagliptin and metformin were supplied by
Merck Research Labs (Rahway, NJ).
For RNA and protein analyses by real-time quantitative PCR and Western
blot, respectively, heart tissue was obtained from separate groups of normo-
glycemic Dpp4
/ or Dpp4
/ mice fed regular food, or wild-type C57BL/6
mice exposed to HFD for 4 weeks, given a single dose of STZ (75 mg/kg), and
then treated with either HFD alone, or HFD plus 1) metformin, 2) sitagliptin,
or 3) the GLP-1R agonist liraglutide (Novo Nordisk, Novo Alle, Bagsvaerd,
Denmark) (10), 75 g/kg i.p. twice daily for an additional 7 days. All animals
were killed by exposure to carbon dioxide.
Isolated heart preparations were from 12-week-old male Dpp4
/ and
Dpp4
/ littermates or separate groups of wild-type C57BL/6 mice. Only
isolated mouse hearts exhibiting a heart rate 350 bpm were used. Wild-type
C57BL/6 mice were treated with an intraperitoneal injection of either sitaglip-
tin (20 mg/kg) or metformin (125 g/kg) or saline at 24 h and 1 h before heart
excision.
Metabolic measurements. Oral glucose tolerance tests were performed in
sitagliptin- or metformin-treated wild-type C57BL/6 mice and untreated con-
trols. Mice were fasted for 16 h and administered glucose (1.5 mg/g) via oral
gavage. A1C and blood glucose levels were measured on whole blood using
the DCA 2000 Analyzer and a Glucometer (both Bayer, Toronto, ON,
Canada). GLP-1 (7-36)amide levels were measured by a Meso Scale Discovery
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FIG. 1. Dpp4
/ mice exhibit increased survival after myocardial ischemic injury. A: Heart weight (HW)–to–body weight (BW) ratios in
12-week-old Dpp4
/ versus Dpp4
/ mice not exposed to LAD ligation. B: Experimental scheme for analysis of normoglycemic Dpp4
/ and
Dpp4
/ mice on a regular diet. C: MI was induced by permanent coronary artery ligation (LAD) and survival was assessed in male and female
12-week-old Dpp4
/ and Dpp4
/ mice over the subsequent 4 weeks. D: Hypertrophy is observed in Dpp4
/ and Dpp4
/ mice after MI. E: Infarct
size was determined through quantitative histological analysis of hearts from male and female Dpp4
/ and Dpp4
/ mice. *P < 0.05; numbers
in brackets correspond to number of male and female mice (combined) per treatment.
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from mice fasted for 5 h.
Coronary artery ligation. Experimental MI was induced by left anterior
descending (LAD) artery ligation as described (22). Brieﬂy, 12-week-old male
and female Dpp4
/ and Dpp4
/ mice were anesthetized using 1% isoﬂurane,
intubated, and ventilated with room air using a positive-pressure respirator
(model 680; Harvard, South Natick, MA). Left thoracotomy was performed via
the fourth intercostal space; the lungs were retracted to expose the heart, and
the pericardium was opened. The LAD was ligated with an 8–0 silk suture
near its origin between the pulmonary outﬂow tract and the edge of the left
atrium. Acute myocardial ischemia was considered successful when the
anterior wall of the left ventricle (LV) turned pale. The lungs were inﬂated by
an increase in positive end-expiratory pressure, and the thoracotomy was
closed. Animals were kept on the ventilator until awake. Sham operation
differed only in that the 7–0 suture was passed under the coronary artery and
then removed.
Ultrasound biomicroscopy in mice after LAD artery ligation. Male
C57BL/6 mice, 10 weeks old, from Taconic (Germantown, NY) were housed
under pathogen-free conditions in micro-isolator cages and maintained on a
12-h light (0700)/dark (1900) cycle. At 11 weeks of age, mice were placed on
either a control diet (Research Diets) or a diet containing sitagliptin (250 mg 
kg
1  day
1) or metformin (450 mg  kg
1  day
1) for 1 week before LAD
ligation. High-frequency ultrasound imaging was carried out on day 4 post-MI.
Mice were killed on day 5 after coronary artery ligation, and hearts were
collected for RNA and protein analyses.
Isolated heart preparations. After administration of heparin (1,000 IU/kg
s.c.) and sodium pentobarbital (200 mg/kg i.p.), hearts were excised, cannu-
lated through the aorta, and perfused at 80 mmHg in a Langendorff apparatus
with gassed (95% O2,5 %C O 2) Krebs-Hensleit buffer (mmol/l: 118 NaCl, 4.7 KCl,
11 glucose, 1.2 MgSO4, 25 NaHCO3, 1.2 KH2PO4, and 2.5 CaCl2) maintained at
37°C (Harvard Apparatus, Holliston, MA) as described (15). For measurement
of isovolumetric pressures, a small plastic balloon was inﬂated in the LV via
a small left atrial incision. Both end systolic (LVESP) and end diastolic
(LVEDP) pressures were monitored, the latter maintained between 4 and 8
mmHg throughout the experiment. LV developed pressure (LVDP) was
calculated as LVESP  LVEDP.
Ischemia reperfusion protocol. Hearts underwent 20- and 40-min equilib-
rium and perfusion phases, respectively, during which hemodynamic param-
eters were recorded. Global ischemia and reperfusion phases were produced
by clamping and restoring inﬂow for 30 and 40 min, respectively. For direct
infusion of sitagliptin (5 mol/l) (versus PBS), the agent was added to the
perfusion buffer for the ﬁnal 20 min of the perfusion phase. Recovery of LVDP
was measured at the end of reperfusion and expressed as % of LVDP at the end
of perfusion (i.e., before ischemia) (15).
Histology. Animals were anesthetized using 3% isoﬂurane/97% air. The chest
was opened to expose the heart, where an apical injection of KCl (1 mol/l) was
used to arrest the heart in diastole. The heart was then perfusion-ﬁxed with 4%
buffered formalin at physiological pressure. Hearts were postﬁxed in formalin,
embedded in parafﬁn, sectioned at 6 m, and stained with hematoxylin and
eosin (H&E) or Masson’s Trichrome. Cardiac morphometry was performed
with LEICA QWin V3 software (2003) using digital planimetry of images
obtained from mid-ventricular cross-sections. Infarcted LV area was calcu-
lated asa%o ftotal LV area.
Quantitative RT-PCR. Total RNA was prepared from mouse heart using
Tri-Reagent (Sigma-Aldrich). First-strand cDNA synthesis used random hex-
amers and the Superscript II (Invitrogen) system. Real-time PCR analysis was
carried out using Taqman gene expression assays and Universal PCR master
mix (Applied Biosystems), using the ABI prism 7900 Sequence Detection
System. Primers used included mouse Akt1 (Mm00437443_m1), Mmp9
(Mm00442991_m1), Ho1 (Mm00516005_m1), Ppar (Mm00440939_m1), Gsk3
(Mm00444911_m1), PI3K (Mm01282781_m1), -actin (Mm00607939_s1) (Ap-
plied Biosystems), and Gapdh (Mm99999915-g1). Relative mRNA transcript
levels were quantiﬁed with the 2
CT method, using -actin as an internal
control.
Western blots. Extracts from whole hearts were prepared as described (23).
After SDS-PAGE, proteins were electrotransferred onto a Hybond-C nitrocel-
lulose membrane (Amersham, Piscataway, NJ). Blots were incubated over
night at 4°C with 1
o antibody (Ab). Horseradish peroxidase–conjugated 2
o Ab
and enhanced chemiluminescence (Amersham, Piscataway, NJ) were used to
detect proteins. Primary Abs include pGSK3 (Ser9) 1:2,000 (Cell Signaling,
Danvers, MA), atrial natriuretic peptide (ANP) 1:500 (Santa Cruz, Santa Cruz,
CA), HO-1 1:5,000 (Stressgen, Ann Arbor, MI), pAKT (Ser 473) and total AKT
1:1,000 (Cell Signaling), and HSP90 1:2,000 (BD Biosciences, San Jose, CA).
Statistical analysis. Data are presented as mean  SE except where noted.
Analyses were performed using Prism software (Version 4.02; GraphPad
Software, San Diego, CA). Differences in the number of surviving animals
were analyzed using Kaplan-Meier Survival analyses. The remaining results
were analyzed using ANOVA followed by Bonferroni’s post hoc tests. P  0.05
was considered statistically signiﬁcant.
RESULTS
Cardiac structure and function in Dpp4
/ mice. We
ﬁrst veriﬁed that Dpp4
/ mice used in our studies re-
tained the phenotype of improved glucose tolerance and
reduced DPP-4 activity as originally described (18). Con-
sistent with previous ﬁndings, oral glucose tolerance was
improved and plasma DPP-4 activity was markedly re-
duced in Dpp4
/ mice (supplemental Fig. 1A–C, available
in an online appendix at http://diabetes.diabetesjournals.
org/cgi/content/full/db09-0955/DC1). Heart weights did not
differ between 12-week-old sex-matched Dpp4
/ and
Dpp4
/ mice (Fig. 1A,P	 NS). High-resolution echocar-
diography did not detect any differences in LV wall thick-
nesses, LV end systolic and end diastolic dimensions,
mitral and aortic ﬂow velocities, LV systolic and diastolic
areas, LV outﬂow tract diameter, aortic ejection time, left
atrial size, or fractional shortening between Dpp4
/ and
Dpp4
/ mice (Table 1, NS for all comparisons). Hence,
genetic disruption of the Dpp4 gene in mice is not associ-
ated with baseline abnormalities in cardiac structure or
function.
Myocardial infarction outcomes in normoglycemic
Dpp4
/ mice. To determine whether disruption of the
Dpp4 gene modiﬁes the response to cardiac injury, we
induced MI in nondiabetic 12-week-old male and female
Dpp4
/ and Dpp4
/ mice via permanent surgical LAD
ligation (Fig. 1B). At the predeﬁned end point of 4 weeks
post-MI, Dpp4
/ mice exhibited an 
20% absolute in-
crease in survival compared with Dpp4
/ littermate
controls (Fig. 1C). Post-MI, the hearts of Dpp4
/ and
TABLE 1
Echocardiography-deﬁned dimensional and functional parame-
ters in Dpp4
/ and Dpp4
/ mice
Dpp4
/ Dpp4
/
n 55
Aortic ﬂow
Aortic outﬂow velocity (cm/s) 72.8  4.4 63.6  2.9
Aortic valve ejection time (ms) 68.5  3.9 69.6  3.6
Mitral ﬂow
Peak E velocity (cm/s) 51.7  2.3 47.7  5.0
Deceleration time (ms) 42.5  3.5 47.1  1.3
LV chamber dimensions by M-mode
Left atrium size (mm) 1.74  0.06 1.66  0.03
LV end diastolic diameter (mm) 3.85  0.22 3.87  0.09
LV end systolic diameter (mm) 2.45  0.18 2.62  0.08
LV outﬂow tract diameter (mm) 1.17  0.03 1.14  0.02
Anterior wall thickness (mm) 0.74  0.30 0.76  0.01
Posterior wall thickness (mm) 0.77  0.04 0.74  0.02
Fractional shortening (%) 36.42  2.17 32.85  1.04
Data are means  SE. Genetic elimination of DPP-4 activity is not
associated with abnormalities in parameters of cardiovascular
function. Transthoracic echocardiographic studies were carried
out in male 12-week-old Dpp4
/ and Dpp4
/ mice. Mice were
lightly anesthetized using 3% isoﬂurane/97% oxygen. Two-dimen-
sional and M-mode echocardiography, as well as pulsed Doppler
analyses, were performed by a blinded observer using a Hewlett-
Packard 5500 ultrasound device (Hewlett-Packard, Palo Alto, CA)
and a 12-MHz phased array and 15-MHz Doppler probes. Three
M-mode recordings of end systolic and end diastolic LV internal
diameters and end diastolic LV posterior wall thickness were
made. A single mean measurement was then calculated for each
mouse. Analysis of data was carried out as previously described
(44,45).
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/ mice underwent similar compensatory hypertro-
phy (Fig. 1D). Although infarct size was reduced in
Dpp4
/ mice, this difference was not statistically signiﬁ-
cant (Fig. 1E).
To explore mechanisms mediating the increased sur-
vival of Dpp4
/ mice post-MI, we analyzed cardiac mRNA
and protein levels of known cardioprotective genes. Nor-
moglycemic nonischemic Dpp4
/ mice exhibited small
but nonsigniﬁcant increases in Akt1, Gsk3, Ppar, PI3K,
and Ho1 transcripts (Fig. 2B–F). Moreover, hearts from
Dpp4
/ mice contained higher levels of phosphorylated
AKT (pAKT), pGSK3, and ANP (Fig. 2G–I), proteins
known to be regulated by GLP-1R agonists (10) and
associated with cardioprotection in vivo (24–27).
Treatment of diabetic mice with metformin or sita-
gliptin pre- and post-MI. Because Dpp4
/ mice are
resistant to the development of STZ-induced diabetes (28),
we assessed whether reduction of DPP-4 activity is car-
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FIG. 2. Dpp4
/ hearts express increased levels of proteins associated with cardiomyocyte survival. A: Experimental outline for analysis of basal
RNA and protein expression in Dpp4
/ and Dpp4
/ mice. Relative levels of mRNA transcripts for Akt1 (B), Gsk3 (C), Ppar (D), PI3k (E),
and Ho1 (F) in nonischemic hearts from 12-week-old Dpp4
/ versus Dpp4
/ mice assessed by quantitative real-time PCR and normalized to
levels of -actin transcripts in the same samples. n  6 per group. Relative levels of pGSK3 (G), ANP (H), and pAKT1 (I) determined by Western
blot analysis of protein extracts from hearts of 12-week-old Dpp4
/ and Dpp4
/ mice are shown. *P < 0.05, n  3 for each genotype.
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/ mice. Wild-type mice
were placed on an HFD for 4 weeks, rendered diabetic
with STZ, and maintained for an additional 12 weeks on
HFD alone or on HFD plus either sitagliptin or metformin
(Fig. 3A). After 8 weeks on drug treatment or HFD alone,
mice were subjected to LAD ligation and observed for an
additional 4 weeks (Fig. 3A). Random blood glucose (Fig.
3B), levels of A1C (Fig. 3C), and oral glucose tolerance
(Fig. 3D–E) were improved to a similar extent with body
weights remaining comparable (Fig. 3F) in mice treated
with sitagliptin or metformin. Moreover, plasma levels of
active GLP-1 (7-36)amide were increased to a similar
extent in sitagliptin- versus metformin-treated mice (Fig.
3G).
Cumulative survival assessed up to 4 weeks after LAD
ligation was improved in mice treated with either sita-
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alone (Fig. 4A). A signiﬁcant increase in heart-to-body
weight ratios post-MI was observed only in diabetic
mice treated with metformin (Fig. 4B). No differences in
infarct size were observed between the three groups
(Fig. 4C).
To identify potential mechanism(s) underlying im-
proved survival post-MI in sitagliptin- and metformin-
treated diabetic mice, we assessed cardiac mRNA and
protein levels of candidate pro-survival genes in separate
groups of diabetic animals treated for 1 week with either
sitagliptin, metformin, or the GLP-1R agonist, liraglutide.
No signiﬁcant changes were detected in mRNA levels of
PI3k, Akt, Ho1, Mmp9, and Ppar after treatment with
these antidiabetic agents (Fig. 5B–F). In contrast, sitaglip-
tin, metformin, and liraglutide increased expression of
ANP (Fig. 5G). Sitagliptin and liraglutide, but not met-
formin, activated the prosurvival kinase AKT (Fig. 5H),
whereas all three drugs increased levels of HO-1 (Fig. 5I).
A modest but nonsigniﬁcant increase in levels of phospho-
GSK3 was also observed with all three antidiabetic
agents (Fig. 5J).
We next examined whether metformin or sitagliptin
treatment of HFD-fed mice produced changes in gene and
protein expression in the mouse heart after LAD ligation
(Fig. 6A). Levels of Ho1 and Gsk3 RNA transcripts were
modestly increased (Fig. 6D and E), whereas Akt1, PI3k,
and Ppar RNA transcripts were signiﬁcantly increased in
the post-ischemic heart after metformin treatment (Fig.
6B, C, and F). In contrast, sitagliptin treatment was not
associated with signiﬁcant changes in levels of cardiopro-
tective mRNA transcripts post-MI (Fig. 6B–F). Neither
metformin nor sitagliptin treatment produced detectable
changes in levels of AKT, ANP, GSK3, or HO-1 proteins
assessed at day 5 post-MI (Fig. 6G–J). Similarly, although
heart rate was increased in metformin-treated mice, we
did not detect other signiﬁcant differences in parameters
of cardiac function in sitagliptin- versus metformin-treated
mice after myocardial infarction (Table 2).
Ischemia-reperfusion injury and metformin versus
DPP-4 inhibition in normoglycemic mouse hearts. To
determine whether cardioprotective actions of sitagliptin
are observed in the normoglycemic murine heart, we
acutely administered sitagliptin, metformin, or saline
(PBS) to nondiabetic wild-type mice in vivo before assess-
ing recovery of LVDP after I/R injury to their hearts ex vivo
(15). Parallel experiments included I/R injury in hearts
from normoglycemic Dpp4
/ and Dpp4
/ animals, as
well as testing cardioprotective actions of an acute ex vivo
sitagliptin infusion (20 min) versus placebo (PBS) imme-
diately before wild-type hearts undergoing I/R injury (Fig.
7A).
Acute administration of metformin or sitagliptin in vivo
improved recovery from subsequent I/R injury in normo-
glycemic mice (Fig. 7B). Recovery of LVDP was also
greater in Dpp4
/ hearts versus Dpp4
/ littermate con-
trols (Fig. 7B). By contrast, sitagliptin administered to the
coronary circulation ex vivo (and immediately before I/R
injury) exerted no direct cardioprotective actions in iso-
lated mouse hearts (Fig. 7C). Taken together, these data
show that the cardioprotective effects of genetic or phar-
macological inhibition of DPP-4 activity are not strictly
glucose dependent and depend on one or more DPP-4–
dependent actions in vivo.
DISCUSSION
Analysis of the cardiovascular proﬁle of antidiabetic
agents involves ascertainment of the effects of each drug
on the myocardium and endothelium, and on secondary
risk factors such as control of blood pressure and choles-
terol. Although preclinical studies may be useful in gener-
ating hypotheses about the putative cardiovascular actions
of different drug classes, the results of subsequent clinical
studies have not always been concordant with predictions
made from preclinical analyses. For example, although
both thiazolidinediones, pioglitazone and rosiglitazone,
exert beneﬁcial effects on inﬂammation and endothelial
function (29), pioglitazone, but not rosiglitazone, is asso-
ciated with reduced cardiovascular events in human stud-
ies (3,30). Similarly, although data from both preclinical
(31) and clinical studies (32) suggests that metformin
therapy may be cardioprotective, the mechanisms through
which metformin therapy is associated with cardioprotec-
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have been associated with increased rates of death from
cardiovascular disease in some (33) but not all studies
(32).
We have now investigated the cardiovascular conse-
quences arising from genetic elimination or pharmacolog-
ical inhibition of DPP-4 activity. DPP-4 has three major
functions; adenosine deaminase binding, peptidase activ-
ity, and extracellular matrix binding, all of which poten-
tially inﬂuence the activity of the immune and/or
endocrine systems (34). Although DPP-4 cleaves and inac-
tivates several cardioactive peptides, including neuropep-
tide Y, brain natriuretic peptide, SDF-1, and GLP-1, there
is little information on the cardiovascular consequences
of reduced or absent DPP-4 activity. Normoglycemic
Dpp4
/ mice exhibit normal cardiac structure and func-
tion in the basal state, yet increased survival after exper-
imental MI. Whether the increased survival after LAD
ligation is directly due to loss of DPP-4 activity per se in
cardiomyocytes or blood vessels, or indirectly due to the
subsequent upregulation of cardioprotective molecules
such as GLP-1 (18) or SDF-1 (35), cannot be inferred from
the present study. Zaruba et al. (35) also observed modest
improvements in survival after experimental MI in
Dpp4
/ mice or in WT mice treated with a DPP-4
inhibitor, and more robust improvements in survival were
observed after administration of G-CSF, ﬁndings attrib-
uted to SDF-1–dependent mobilization of cardiac stem
cells. Our studies extend their observations through exam-
ination of the cardiovascular effects of DPP-4 inhibition in
diabetic mice and by demonstrating that direct sitagliptin
administration into the circulation of the ischemic mouse
heart is not directly cardioprotective ex vivo, suggesting
that acute reduction of cardiac DPP-4 activity is not
sufﬁcient to produce cardioprotection.
Our ﬁndings demonstrating that both sitagliptin and the
GLP-1R agonist liraglutide upregulated levels of cardiopro-
tective proteins in the nonischemic myocardium suggest a
possible role for GLP-1 in the context of enhanced survival
after DPP-4 inhibition and experimental MI. Nevertheless,
we did not observe a sustained induction of cardioprotec-
tive proteins in sitagliptin-treated murine hearts when the
same proteins were examined after MI. Moreover, we did
not detect signiﬁcant changes in infarct size or cardiac
function after MI that might directly account for the
improved survival seen with genetic or chemical reduction
of DPP-4 activity. Hence, the precise mechanisms mediat-
ing the improvements in survival observed after pharma-
cological treatment with sitagliptin in diabetic mice or
genetic reduction of DPP-4 activity in normoglycemic
Dpp4
/ mice require further investigation, ideally
through examination of whether DPP-4 inhibitors exert
cardioprotective actions in Glp1r
/ mice.
Western blot analysis of proteins in nonischemic hearts
demonstrated that both sitagliptin and metformin therapy
induced an overlapping set of cardioprotective proteins.
Metformin is thought to exert its cardioprotective actions
through distinct mechanisms requiring activation of AMP
kinase and endothelial nitric oxide (31). Intriguingly, ad-
ministration of metformin has also been associated with
reduction of DPP-4 activity (36) and increased circulating
levels of GLP-1 in both rodent (37) and clinical studies
(38), and we detected increased levels of GLP-1 in both
metformin- and sitagliptin-treated mice. Accordingly, the
extent to which therapy with sitagliptin and metformin
produces an overlapping spectrum of actions reﬂecting
similarities in their mechanism(s) of action through en-
hanced levels of GLP-1 requires further clariﬁcation.
Both metformin and sitagliptin signiﬁcantly increased
survival in diabetic mice, possibly due to a comparable
reduction in blood glucose achieved with either agent.
Hyperglycemia is a risk factor for a poor outcome after MI
in humans (39), and there is considerable interest in
determining whether intensive glucose control safely and
consistently improves outcomes post-MI (40). Similarly,
hyperglycemia is known to be associated with reduced
survival and impaired LV function in mice after MI (41–
43), and it seems likely that reduction in the severity of
TABLE 2
Ultrasound biomicroscopy-deﬁned cardiac hemodynamic, functional, and dimensional parameters in mice treated with either control,
sitagliptin, or metformin on day 4 post-LAD ligation
Control Sitagliptin Metformin
n 66 5
Aortic ﬂow
Heart rate (bpm) 441  17 423  19 526  23*
VTImax (cm) 2.64  0.14 2.40  0.08 2.39  0.30
Aortic oriﬁce diameter (mm) 1.04  0.04 1.06  0.03 1.04  0.03
LV stroke volume (l) 22.38  1.24 21.10  1.33 20.34  3.07
Cardiac output (ml/min) 9.82  0.46 8.95  0.71 10.70  1.66
Mitral ﬂow
Heart rate (bpm) 447  13 433  16 792  33
Peak E velocity (cm/s) 67.6  3.0 62.6  2.4 53.4  6.2
Peak A velocity (cm/s) 48.0  49 36.0  40 54.6  73
Peak E/A ratio 1.47  0.15 1.89  0.29 0.99  0.08
LV chamber dimensions by M-mode
Heart rate (bpm) 493  35 458  15 541  18
LV end diastolic diameter (mm) 4.26  0.15 4.28  0.19 4.43  0.16
LV end systolic diameter (mm) 3.54  0.27 3.68  0.21 3.89  0.22
LV fractional shortening (%) 17.3  3.5 14.2  1.2 12.4  2.4
Data are means  SE. The 12-week-old C57Bl/6 mice treated with control, sitagliptin, or metformin for 1 week before experimental cardiac
ischemic injury were subjected to high-frequency ultrasound imaging. VTImax, velocity-time integral of Doppler ﬂow waveform by tracing the
maximal velocity. In mitral inﬂow, the peak E velocity represents the maximal velocity of the early diastolic wave caused by active left
ventricular relaxation. The peak A velocity represents the maximal velocity caused by atrial contraction in late diastole. Acquisition of images
and analysis of data were carried out as previously described (44,45). *P  0.05 vs. control.
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independent of the antidiabetic mechanisms unique to
each agent under study.
In contrast, the increased survival observed in normo-
glycemic Dpp4
/ mice after MI supports the concept that
reduction of DPP-4 activity may be cardioprotective in the
absence of hyperglycemia (35). Similarly, our observations
demonstrating that genetic or chemical inhibition of DPP-4
is associated with enhanced recovery of LVDP in the
normoglycemic ischemic murine heart ex vivo suggest that
DPP-4 modiﬁes cardiovascular outcomes independent of
glucoregulation and provide a useful model for future
studies. Given the increasing interest in using strategies
based on DPP-4 inhibition for the treatment of diabetes, a
more detailed understanding of the role of DPP-4 in the
normal and diabetic cardiovascular system is clearly
warranted.
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